Bluestar Genomics is Other Healthcare Technology Systems in United States that focus on curative therapies business. Founded in 2016. They cover business area such as developer, liquid biopsy test, comprehensive disease information, cell-free dna testing, proprietary next-generation epigenomic and big datum approach, non-invasive molecular diagnostic testing, healthcare provider, deadly cancer, curative therapy.
Other Healthcare Technology Systems
2016
( 8 years old in 2024 )
Curative Therapies
-
155 Bovet Road
Suite 400
San Mateo, CA 94402
United States
Private
developerliquid biopsy testcomprehensive disease informationcell-free dna testingproprietary next-generation epigenomic and big datum approachnon-invasive molecular diagnostic testinghealthcare providerdeadly cancercurative therapy
* We use standard office opening hours in near Bluestar Genomics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Bluestar Genomics is Other Healthcare Technology Systems business from United States that founded in 2016 (8 years old in 2024), Bluestar Genomics business is focusing on Curative Therapies.
Bluestar Genomics headquarter office and corporate office address is located in 155 Bovet Road Suite 400 San Mateo, CA 94402 United States.
Bluestar Genomics was founded in United States.
In 2024, Bluestar Genomics is currently focus on curative therapies sector.
Above is snippet of Google Trends for "curative therapies" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Bluestar Genomics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
